{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T10:23:15Z","timestamp":1792664595377,"version":"4.5.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008497","name":"Boston Scientific Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008497","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003083","name":"European Association of Urology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003083","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.euf.2025.12.007","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T21:08:34Z","timestamp":1766005714000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Harnessing Artificial Intelligence for Risk Stratification and Outcome Prediction in Urologic Cancers: A Systematic Review"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-2792-9828","authenticated-orcid":false,"given":"Navid","family":"Roessler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Miszczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichiro","family":"Miyajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Dematteis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed R.","family":"Alfarhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Cormio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrahman S.","family":"Alqahtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s","family":"Fazekas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor M.","family":"Schuettfort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malte W.","family":"Vetterlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yipeng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veeru","family":"Kasivisvanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantinos","family":"Zamboglou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Leapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margit","family":"Fisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Eckstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahul B.","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni Enrico","family":"Cacciamani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre I.","family":"Karakiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawel","family":"Rajwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2025.12.007_b0005","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.euf.2024.11.003","article-title":"Trimodality therapy versus radical cystectomy for muscle-invasive bladder cancer: a systematic review and meta-analysis of matched cohort studies","volume":"11","author":"Matsukawa","year":"2025","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euf.2025.12.007_b0010","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.euf.2024.09.006","article-title":"Comparative effectiveness of bacillus Calmette-Gu\u00e9rin and sequential intravesical gemcitabine and docetaxel for treatment-na\u00efve intermediate-risk non-muscle-invasive bladder cancer","volume":"11","author":"Kolanukuduru","year":"2025","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euf.2025.12.007_b0015","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S1470-2045(19)30738-7","article-title":"Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study","volume":"21","author":"Str\u00f6m","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2025.12.007_b0020","doi-asserted-by":"crossref","unstructured":"Packiam VT, McElree IM, Ghodoussipour S, et al. Presence of an artificial intelligence-powered predictive biomarker is associated with a poor response to intravesical bacillus Calmette-Guerin but not to intravesical sequential gemcitabine\/docetaxel in patients with high-grade non-muscle-invasive bladder cancer. Eur Urol Oncol. In press. https:\/\/doi.org\/10.1016\/j.euo.2025.04.006.","DOI":"10.1016\/j.euo.2025.04.006"},{"key":"10.1016\/j.euf.2025.12.007_b0025","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst Rev"},{"key":"10.1016\/j.euf.2025.12.007_b0030","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.euf.2025.12.007_b0035","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.euf.2025.12.007_b0040","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1200\/JCO.24.00365","article-title":"Development and validation of an artificial intelligence digital pathology biomarker to predict benefit of long-term hormonal therapy and radiotherapy in men with high-risk prostate cancer across multiple phase III trials","volume":"43","author":"Armstrong","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.12.007_b0045","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300023","article-title":"Artificial intelligence predictive model for hormone therapy use in prostate cancer","volume":"2","author":"Spratt","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.euf.2025.12.007_b0050","first-page":"192","article-title":"Predicting response to intravesical bacillus Calmette-Gu\u00e9rin in high-risk nonmuscle-invasive bladder cancer using an artificial intelligence-powered pathology assay: development and validation in an international 12-center cohort","volume":"213","author":"Lotan","year":"2025","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2025.12.007_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100157","article-title":"Convolutional neural network quantification of Gleason pattern 4 and association with biochemical recurrence in intermediate-grade prostate tumors","volume":"36","author":"Chen","year":"2023","journal-title":"Mod Pathol"},{"key":"10.1016\/j.euf.2025.12.007_b0060","doi-asserted-by":"crossref","first-page":"11035","DOI":"10.1038\/s41598-023-38097-7","article-title":"Recurrence prediction in clear cell renal cell carcinoma using machine learning of quantitative nuclear features","volume":"13","author":"Matsubara","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.euf.2025.12.007_b0065","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1136\/jclinpath-2018-205328","article-title":"Deep learning for detecting tumour-infiltrating lymphocytes in testicular germ cell tumours","volume":"72","author":"Linder","year":"2019","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.euf.2025.12.007_b0070","doi-asserted-by":"crossref","first-page":"S979","DOI":"10.1016\/j.annonc.2024.08.1702","article-title":"Validation of a digital pathology-based multimodal artificial intelligence (MMAI) prostate biopsy biomarker in a prospective, real-world Swedish prostate cancer (PCa) cohort treated with radical prostatectomy","volume":"35","author":"Bjartell","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euf.2025.12.007_b0075","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1097\/JU.0000000000004435","article-title":"An artificial intelligence-digital pathology algorithm predicts survival after radical prostatectomy from the Prostate, Lung, Colorectal, and Ovarian Cancer Trial","volume":"213","author":"Li","year":"2025","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2025.12.007_b0080","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.euo.2024.01.004","article-title":"External validation of a digital pathology-based multimodal artificial intelligence architecture in the NRG\/RTOG 9902 phase 3 trial","volume":"7","author":"Ross","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euf.2025.12.007_b0085","article-title":"Prostate cancer risk stratification in NRG oncology phase III randomized trials using multimodal deep learning with digital histopathology","volume":"8","author":"Tward","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.euf.2025.12.007_b0090","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1158\/1078-0432.CCR-19-2659","article-title":"Computationally derived image signature of stromal morphology is prognostic of prostate cancer recurrence following prostatectomy in African American patients","volume":"26","author":"Bhargava","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euf.2025.12.007_b0095","doi-asserted-by":"crossref","first-page":"11006","DOI":"10.1038\/s41598-025-95267-5","article-title":"Clinical implications of deep learning based image analysis of whole radical prostatectomy specimens","volume":"15","author":"Kwak","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.euf.2025.12.007_b0100","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.euf.2021.04.016","article-title":"Computationally derived cribriform area index from prostate cancer hematoxylin and eosin images is associated with biochemical recurrence following radical prostatectomy and is most prognostic in Gleason grade group 2","volume":"7","author":"Leo","year":"2021","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euf.2025.12.007_b0105","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.euo.2024.08.004","article-title":"Comparison of pathologist and artificial intelligence-based grading for prediction of metastatic outcomes after radical prostatectomy","volume":"8","author":"Oliveira","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euf.2025.12.007_b0110","article-title":"Digital pathology-based multimodal artificial intelligence scores and outcomes in a randomized phase III trial in men with nonmetastatic castration-resistant prostate cancer","volume":"9","author":"Feng","year":"2025","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.euf.2025.12.007_b0115","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41698-021-00174-3","article-title":"Computer extracted gland features from H&E predicts prostate cancer recurrence comparably to a genomic companion diagnostic test: a large multi-site study","volume":"5","author":"Leo","year":"2021","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.euf.2025.12.007_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100241","article-title":"Artificial intelligence-based PTEN loss assessment as an early predictor of prostate cancer metastasis after surgery: a multicenter retrospective study","volume":"36","author":"Patel","year":"2023","journal-title":"Mod Pathol"},{"key":"10.1016\/j.euf.2025.12.007_b0125","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.humpath.2022.01.009","article-title":"Development and validation of a quantitative reactive stroma biomarker (qRS) for prostate cancer prognosis","volume":"122","author":"Ruder","year":"2022","journal-title":"Hum Pathol"},{"key":"10.1016\/j.euf.2025.12.007_b0130","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s43856-021-00005-3","article-title":"Predicting prostate cancer specific-mortality with artificial intelligence-based Gleason grading","volume":"1","author":"Wulczyn","year":"2021","journal-title":"Commun Med (Lond)"},{"key":"10.1016\/j.euf.2025.12.007_b0135","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.eururo.2024.06.019","article-title":"Meta-analysis of individual patient-level data for a multimodal artificial intelligence biomarker in high-risk prostate cancer: results from six NRG\/RTOG phase 3 randomized trials","volume":"86","author":"Spratt","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.12.007_b0140","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.euo.2024.11.009","article-title":"Digital pathology-based artificial intelligence biomarker validation in metastatic prostate cancer","volume":"8","author":"Markowski","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euf.2025.12.007_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110618","article-title":"Validation of an artificial intelligence-based prognostic biomarker in patients with oligometastatic castration-sensitive prostate cancer","volume":"202","author":"Wang","year":"2025","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.euf.2025.12.007_b0150","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41746-022-00613-w","article-title":"Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials","volume":"5","author":"Esteva","year":"2022","journal-title":"NPJ Digit Med"},{"key":"10.1016\/j.euf.2025.12.007_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpi.2022.100135","article-title":"Bladder cancer prognosis using deep neural networks and histopathology images","volume":"13","author":"Barrios","year":"2022","journal-title":"J Pathol Inform"},{"key":"10.1016\/j.euf.2025.12.007_b0160","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.euf.2020.12.008","article-title":"Deep learning-based recurrence prediction in patients with non-muscle-invasive bladder cancer","volume":"8","author":"Lucas","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euf.2025.12.007_b0165","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3390\/biomedicines12020360","article-title":"Prediction of non-muscle invasive papillary urothelial carcinoma relapse from hematoxylin-eosin images using deep multiple instance learning in patients treated with bacille Calmette-Gu\u00e9rin immunotherapy","volume":"12","author":"Drachneris","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.euf.2025.12.007_b0170","doi-asserted-by":"crossref","first-page":"5807","DOI":"10.3390\/cancers14235807","article-title":"Accurate diagnosis and survival prediction of bladder cancer using deep learning on histological slides","volume":"14","author":"Zheng","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.euf.2025.12.007_b0175","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/s41416-021-01640-2","article-title":"Machine learning-based pathomics signature could act as a novel prognostic marker for patients with clear cell renal cell carcinoma","volume":"126","author":"Chen","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.euf.2025.12.007_b0180","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/ijc.33288","article-title":"Clinical use of a machine learning histopathological image signature in diagnosis and survival prediction of clear cell renal cell carcinoma","volume":"148","author":"Chen","year":"2021","journal-title":"Int J Cancer"},{"key":"10.1016\/j.euf.2025.12.007_b0185","unstructured":"Chen M, Wang K, Kapur P, Brugarolas J, Hannan R, Wang J. A multimodal ensemble approach for clear cell renal cell carcinoma treatment outcome prediction. ArXiv 2024;arXiv:2412.07136v1."},{"key":"10.1016\/j.euf.2025.12.007_b0190","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1158\/1078-0432.CCR-20-4119","article-title":"Development of a histopathology informatics pipeline for classification and prediction of clinical outcomes in subtypes of renal cell carcinoma","volume":"27","author":"Marostica","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euf.2025.12.007_b0195","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_438516","article-title":"Applications of artificial intelligence in prostate cancer care: a path to enhanced efficiency and outcomes","volume":"44","author":"Riaz","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.euf.2025.12.007_b0200","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","article-title":"[(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study","volume":"19","author":"Hofman","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2025.12.007_b0205","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.clgc.2018.09.014","article-title":"Results of a prospective phase 2 pilot trial of (177)Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer including imaging predictors of treatment response and patterns of progression","volume":"17","author":"Emmett","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euf.2025.12.007_b0210","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1200\/JCO.22.01649","article-title":"Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer","volume":"41","author":"Chi","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.12.007_b0215","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJMoa2214676","article-title":"Rucaparib or physician's choice in metastatic prostate cancer","volume":"388","author":"Fizazi","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2025.12.007_b0220","unstructured":"Spratt DE, Srinivas S, Schaeffer EM, et al. NCCN clinical practice guidelines in oncology (NCCN Guidelines\u00ae). Prostate cancer version 2.2025\u2014April 16, 2025. NCCN; 2025."},{"key":"10.1016\/j.euf.2025.12.007_b0225","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S1470-2045(21)00274-6","article-title":"Nomograms to predict outcomes after (177)Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study","volume":"22","author":"Gafita","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2025.12.007_b0230","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(24)00326-7","article-title":"Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study","volume":"25","author":"Karpinski","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2025.12.007_b0235","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.euo.2024.05.004","article-title":"Effectiveness and cost-effectiveness of artificial intelligence-assisted pathology for prostate cancer diagnosis in Sweden: a microsimulation study","volume":"8","author":"Du","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euf.2025.12.007_b0240","unstructured":"ArteraAI. Artera presenting validation data at 2025 ASCO annual meeting highlighting how multimodal AI platform (MMAI) is advancing personalized cancer care. https:\/\/www.urotoday.com\/conference-highlights\/asco-2025\/asco-2025-press-releases\/160787-artera-presenting-validation-data-at-2025-asco-annual-meeting-highlighting-how-multimodal-ai-platform-mmai-is-advancing-personalized-cancer-care.html."},{"key":"10.1016\/j.euf.2025.12.007_b0245","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.euo.2025.03.007","article-title":"Oncological outcomes in bacillus Calmette-Gu\u00e9rin-na\u00efve high-risk non-muscle-invasive bladder cancer patients: a systematic review on current treatment strategies and future perspectives","volume":"8","author":"Longoni","year":"2025","journal-title":"Eur Urol Oncol"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456925003621?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456925003621?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T10:50:06Z","timestamp":1773917406000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456925003621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":49,"alternative-id":["S2405456925003621"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2025.12.007","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Harnessing Artificial Intelligence for Risk Stratification and Outcome Prediction in Urologic Cancers: A Systematic Review","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2025.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}